The European AI in Genomics market is rapidly expanding, projected to grow from $448.48 million in 2025 to an impressive $9,568.11 million by 2034, with a remarkable compound annual growth rate (CAGR) of 40.5% from 2026 to 2034.
This growth is driven by the integration of artificial intelligence technologies, such as machine learning and natural language processing, into genomics. These technologies are essential for analyzing the vast amounts of data generated by next-generation sequencing, facilitating advancements in drug discovery, diagnostics, and personalized medicine. The European Union’s robust digital infrastructure, highlighted by high internet usage, supports the necessary cloud-based platforms for these AI applications.
Key factors fueling market expansion include the rising prevalence of genetic disorders and cancer, which necessitate more accurate diagnostic methods. AI algorithms enhance the ability to identify genetic mutations linked to various cancers, enabling tailored treatment approaches. Additionally, government initiatives and funding, such as the Horizon Europe program, are fostering a supportive environment for genomic research and innovation, further promoting the adoption of AI technologies.
However, challenges such as stringent data privacy regulations and high implementation costs pose significant barriers to growth. The General Data Protection Regulation (GDPR) complicates the use of genomic data, requiring careful management of consent and compliance, which can hinder the development of diverse datasets needed for effective AI training. Balancing these regulatory demands with the need for innovation remains a critical challenge for the industry.